Rabeca 20

Indications of Rabeca 20

Rabeprazole antigastric tablets are suitable for the treatment of: 
 *active duodenal ulcer 
 *active benign gastric ulcer 
 *symptomatic erosive or ulcerative gastroesophageal reflux disease (GERD). 
 *Long-term treatment of gastroesophageal reflux disease (GERD maintenance) 
 *Symptomatic treatment of moderate to very severe gastroesophageal reflux disease (symptomatic     GERD) 
 *Zollinger-Ellison syndrome 
 *Combine with appropriate antibacterial therapy to eradicate Helicobacter pylori Helicobacter pylori             patients.

 

Pharmaceutical Name

Square Pharmaceuticals Ltd.

 

Pharmacology

Rabeprazole inhibits gastric acid secretion by inhibiting the secretion of gastric ATPase H + / K + on the surface of gastric parietal cells. Since this enzyme is considered to be an acid (proton) pump in parietal cells, rabeprazole is classified as a gastric proton pump inhibitor.

 

Dosage & Administration of Rabeca 20

Active Duodenal Ulcer and Active Benign Gastric Ulcer: The recommended oral dose for both bioactive duodenal ulcer and active benign gastric ulcer is 20 mg to be taken once daily in the morning. Most patients with active duodenal ulcer heal within four weeks. However, a few patients may require an additional four weeks of therapy to achieve healing. Most patients with active benign gastric ulcer heal within six weeks. However, again a few patients may require an additional six weeks of therapy to achieve healing.

Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The recommended oral dose for this condition is 20 mg to be taken once daily for four to eight weeks.

Gastro-Esophageal Reflux Disease Long-term Management (GERD Maintenance): For long-term management, a maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used depending upon patient response.

Symptomatic treatment of moderate to very severe Gastro-Esophageal Reflux Disease (symptomatic GERD): 10 mg once daily in patients without oesophagitis. If symptom control has not been achieved during four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on-demand regimen taking 10 mg once daily when needed.

Zollinger-Ellison Syndrome: The recommended adult starting dose is 60 mg once a day. The dose may be titrated upwards to 120 mg/day based on individual patient needs. Single daily doses up to 100 mg/day may be given. 120 mg dose may require divided doses, 60 mg twice daily. Treatment should continue for as long as clinically indicated.

Eradication of H. pylori: Patients with H. pylori infection should be treated with eradication therapy. The following combination given for 7 days is recommended. Rabeprazole sodium 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1g twice daily.

For indications requiring once-daily treatment Rabeprazole tablets should be taken in the morning, before eating; and although neither the time of day nor food intake was shown to have any effect on rabeprazole sodium activity, this regimen will facilitate treatment compliance. Patients should be cautioned that the Rabeprazole tablets should not be chewed or crushed, but should be swallowed whole.

 

Interactions of Rabeca 20

Wheezing has a profound and long-lasting inhibitory effect on gastric acid secretion. Interactions can occur with compounds whose absorption depends on the pH value. The combination of rabeprazole sodium and ketoconazole or itraconazole can cause a significant decrease in antifungal plasma levels. Therefore, when ketoconazole or itraconazole is taken with Respite, individual patients may need to be monitored to determine whether the dose needs to be adjusted. No interaction with liquid antacids was observed. The absorption of atazanavir depends on the pH value. Therefore, PPIs including rabeprazole should not be combined with atazanavir.

 

Contraindications

Allergy to active ingredients or any excipient. Rabeprazole is contraindicated during pregnancy and lactation.

 

Side Effects of Rabeca 20

Generally speaking, rabeprazole is well tolerated in both short-term and long-term studies. Rabeprazole can sometimes cause headache, diarrhea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness, and dizziness.

 

Pregnancy

U.S. FDA pregnancy category "C" animal studies have found no evidence that rabeprazole causes impaired fertility or harm to the fetus. However, there are no adequate and well-controlled studies on pregnant women. Rabeprazole is likely to be excreted in human milk, so a decision must be made whether to stop breastfeeding or the drug, taking into account the importance of the drug to the mother.

 

Precautions

Administration of Rabeprazole Sodium to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Caution should be exercised in patients with severe hepatic impairment.

 

Therapeutic Class

Proton Pump Inhibitor

 

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

 

Generic Name of Rabeca 20

Rabeprazole Sodium

 

Related Products

• Xorel 20
• Acifix Tab
• Finix 20 Capsule
• Xorel 20 Tablet